AzTrials
AzTrials

Vasectomy ReversalPhase 4NCT04788823

The Impact of Prednisone on Semen Parameters and Pregnancy Rates Post Vasectomy Reversal

A Phase 4 study testing Prednisone in people with Vasectomy Reversal, run by Charitable Union for the Research and Education of Peyronie's Disease at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

1. Determine impact of prednisone on semen parameters post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols). 2. Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3… Read more about this study

Who is it for?
Ages 18 to 65 years, men onlyHealthy volunteers can take part
Conditions the study is for
Vasectomy Reversal
What is being tested?
Prednisone
Could I receive a placebo?
No, everyone receives an active treatment
How many people
75 participants
Where
1 siteUnited States
Study dates
24 Feb 2021to 13 Aug 2026
Phase
Phase 4
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Men only
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Men undergoing a first-time vasectomy reversal at the Male Fertility and Peyronie's Clinic
  • 18-65 years of age
  • Current sexual partner with desire to achieve pregnancy immediately
  • Intent of reversal to restore fertility
  • Partner <36 years of age
  • Partner with no known fertility issues
  • Prior history of paternity

Who cannot join

  • Current corticosteroid use
  • Prior vasectomy reversal
  • Prior chemotherapy
  • Testosterone use within 1 year of the vasectomy reversal
  • Solitary testicle
  • History of diabetes mellitus
Show all 10Show fewer
  • History of systemic fungal infection
  • Hypertension
  • Any degree of diagnosed renal insufficiency
  • Partner on birth control within past 3 months

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Cure PD

    Orem, Utah, 84057

Other trials in United States

About this study

Official title: The Impact of Prednisone on Semen Parameters and Pregnancy Rates Post Vasectomy Reversal: A Randomized, Controlled Trial

  1. Determine impact of prednisone on semen parameters post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
  2. Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).
  3. Assess adverse events with prednisone utilization
Read the detailed description
  1. Introduction

This document is a protocol for a randomized, controlled clinical trial. This study will be carried out in accordance with the procedures described in this protocol, applicable United States government regulations and Western International Review Board policies and procedures.

1.1 Background and Clinical Need for the Current Study

Currently, vasectomy reversals are a common surgical treatment performed to restore fertility in men who have previously undergone vasectomies. Post-operatively, sperm are seen in the ejaculate in the majority of men undergoing a reversal, however, sperm counts commonly fluctuate over time. In a percentage of men, counts will ultimately decline to 0 over time. Although the exact cause of this decline is unknown, it is felt to be secondary to tissue remodeling and/or inflammation leading to stenosis of the anastomotic repair. To address this issue, clinicians have used prednisone for several decades. Despite the long-standing use, very few publications have assessed the overall efficacy of this therapy on improving outcomes. The objective of the current study is to perform a much more robust assessment as to the true risks and benefits of this therapy in improving post-operative outcomes.

1.2 Investigational Treatments

Men who are post vasectomy reversal will be treated with either no therapy (control) or one of three separate protocols with prednisone.

1.3 Preliminary Data

A very limited amount of data exists regarding the efficacy of corticosteroids in improving outcomes post vasectomy reversal. The earliest known study involved the use of cortisone in 8 dogs who underwent vasovasostomy procedures. Results showed that 63% of vasa were patent in the steroid group compared to 43% in control animals (not statistically significant). A second study administered prednisone to 20 men post vasectomy reversal and compared against 20 men who had previously undergone reversal but were not treated with prednisone. Results showed improved sperm counts (statistically significant) without statistically significant differences in pregnancy rates. And finally, a third study performed a retrospective analysis in 89 men who underwent reversals over a period of 11 years. Results demonstrated increases in total motile sperm counts, with greater improvements noted among men who exhibited the presence of sperm at the time of prednisone administration compared to those with 0 sperm.

These data are limited by several factors. The first study listed also performed a pathologic analysis and failed to demonstrate any differences in the extent of fibrosis. The second study was performed in a sequential manner, where outcomes may have just been reflective of learning curve improvements, and improvements were no longer present after the steroid was discontinued. The third study was retrospective in nature, and therefore is limited by significant biases (i.e. only men with low counts received the treatment, which leads to an effect bias). All series were very small and lacked statistical power.

Despite these limited data, the use of prednisone post vasectomy reversal is a common, widespread practice among reversal surgeons.

1.4 Study Rationale and Risk Analysis (Risks to Benefits Ratio)

The study is currently designed to address an important clinical question. Specifically, does the addition of prednisone post-operatively lead to improved semen and pregnancy outcomes. Additionally, does the addition of prednisone lead to temporary or permanent improvements. Regarding potential risks, the use of prednisone will be limited to shorter durations of therapy. Potential risks in a young, healthy population are low. Specifically, an analysis of men 20-64 found that the risks of prednisone include 3 GI bleeds per 100 person years, <1 with a severe infection, and <1 with heart failure. Our study will not include as high of a dosage or duration of therapy shown in this prior risk study, and as such, the true risks are anticipated to be small (if any).

Being tested
Prednisone

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PrednisoneDrug

    Treatment groups will be administered different dosages of Prednisone post vasectomy reversal.

Study groups in NCT04788823
Study groupRoleWhat they receive
ControlNo interventionGroup 1 will represent controls and will not receive prednisone in the 3-year post-op period.
Prednisone Monthly - ScheduledExperimentalGroup 2 will receive 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be given at the beginning of months 0, 2, and 4 and will be self-administered.
Receives: Drug: Prednisone
Prednisone Monthly - As NeededExperimentalGroup 3 will receive a maximum of 3, one-month courses of prednisone (20 mg daily x 1 week, 10 mg daily x 1 week, 5 mg x 2 weeks). These will be administered based on sequential semen analyses. If a semen analysis demonstrates a drop in concentration from a prior analysis or if it shows a 0 concentration, the course will be administered.
Receives: Drug: Prednisone
Prednisone Every Other WeekExperimentalGroup 4 will receive alternating 1 week dosages of prednisone (1 week on, 1 week off - 5 mg daily only) for a total of 24 weeks
Receives: Drug: Prednisone

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Impact of Prednisone on semen concentration post vasectomy reversal

    Determine impact of prednisone on semen concentration post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).

    Measured: 3 years

  2. Impact of prednisone on pregnancy rates post vasectomy reversal.

    Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).

    Measured: 3 Years

  3. Assess adverse events with prednisone utilization

    Assess adverse events with prednisone utilization

    Measured: 3 years

Secondary outcomes (3)
  1. Impact of Prednisone on semen concentration post vasectomy reversal

    Determine impact of prednisone on semen concentration post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).

    Measured: 1 year

  2. Impact of prednisone on pregnancy rates post vasectomy reversal.

    Determine impact of prednisone on pregnancy rates post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).

    Measured: 1 year

  3. Impact of Prednisone on semen concentration post vasectomy reversal

    Determine impact of prednisone on semen concentration post vasectomy reversal (evaluated both using prednisone as a combined cohort as well as via 3 separate protocols).

    Measured: Up to 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Mar 2021
  2. Study start24 Feb 2021
  3. Primary completion13 Aug 2026
  4. Study completion13 Aug 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
The study cohort will be randomized to one of 4 arms: control or 3 different drug protocols.
Masking
None (open label)
Enrolment
75 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04788823
Sponsor's protocol ID
CUREPD 102
Status last verified
Aug 2026
First submitted
3 Mar 2021
Last updated
26 Aug 2026
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
No

Publications

  • Trost L, Helo S, Brearton K, Warner R, Ziegelmann M, Kohler T, Savage J. Impact of prednisone on vasectomy reversal outcomes (iPRED study): results from a randomized, controlled clinical trial. Fertil Steril. 2025 May;123(5):804-811. doi: 10.1016/j.fertnstert.2024.11.019. Epub 2024 Nov 20.

    PubMed 39577828

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Prednisone in people with Vasectomy Reversal, run by Charitable Union for the Research and Education of Peyronie's Disease at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Impact of Prednisone on semen concentration post vasectomy reversal (time frame: 3 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04788823, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in